Shopping Cart
Remove All
Your shopping cart is currently empty
ECI830
Catalog No. T204836 Copy Product Info
🥰Excellent
ECI830 is a highly potent and selective oral small-molecule CDK2 inhibitor. By inhibiting CDK2 activity, ECI830 induces G1/S phase cell cycle arrest, thereby blocking DNA replication and tumor proliferation. ECI830 is suitable for use in studies of HR+/HER2- breast cancer and tumors with CCNE1 amplification.
ECI830
Copy Product Info🥰Excellent
Catalog No. T204836
ECI830 is a highly potent and selective oral small-molecule CDK2 inhibitor. By inhibiting CDK2 activity, ECI830 induces G1/S phase cell cycle arrest, thereby blocking DNA replication and tumor proliferation. ECI830 is suitable for use in studies of HR+/HER2- breast cancer and tumors with CCNE1 amplification.
Cas No. 3054692-62-2
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $283 | 10-14 weeks | 10-14 weeks | |
| 5 mg | $676 | 10-14 weeks | 10-14 weeks | |
| 25 mg | $1,550 | 10-14 weeks | 10-14 weeks | |
| 100 mg | $3,380 | 10-14 weeks | 10-14 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | ECI830 is a highly potent and selective oral small-molecule CDK2 inhibitor. By inhibiting CDK2 activity, ECI830 induces G1/S phase cell cycle arrest, thereby blocking DNA replication and tumor proliferation. ECI830 is suitable for use in studies of HR+/HER2- breast cancer and tumors with CCNE1 amplification. |
| In vitro | ECI830 demonstrated significant antiproliferative activity in CCNE1-amplified ovarian cancer cell lines (OVCAR3) and lung cancer cell lines (H810). [1] The combination of ECI830 and ribociclib produced a synergistic effect in HR+/HER2– breast cancer cells, effectively inhibiting cell growth. [2] |
| In vivo | In a xenograft model of HR+/HER2- breast cancer cell line (MCF7) resistant to standard therapy, the combination of ECI830 and ribociclib exhibited synergistic effects, significantly inhibiting tumor growth. [1] Treatment with ECI830 in combination with ribociclib significantly regulated pRB1 in HR+/HER2⁻ breast cancer CDX and PDX models, demonstrating potent antitumor activity. ECI830 monotherapy effectively inhibited tumor growth in CCNE1-amplified tumor models.[2] |
| Molecular Weight | 384.43 |
| Formula | C19H24N6O3 |
| Cas No. | 3054692-62-2 |
| Smiles | O=C1C2(C=3C(N1[C@H]4C[C@H](O)CCC4)=NC(NC=5C(OCC)=NNC5)=NC3)CC2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy ECI830 | purchase ECI830 | ECI830 cost | order ECI830 | ECI830 chemical structure | ECI830 in vivo | ECI830 in vitro | ECI830 formula | ECI830 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.